Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer

European Urology

Volumn 70, Issue 4, 2016, Pages 599-608

  Welti, Jonathan ^a   Rodrigues, Daniel Nava ^a   Sharp, Adam ^a   Sun, Shihua ^b   Lorente, David ^a,c   Riisnaes, Ruth ^a   Figueiredo, Ines ^a   Zafeiriou, Zafeiris ^a   Rescigno, Pasquale ^a   de Bono, Johann S ^a   Plymate, Stephen R ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Androgen receptor; Androgen receptor variant 7; Castration resistant prostate cancer; Metastatic biopsy; Predictor of outcome; Treatment resistance

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR SPLICE VARIANT 7; BIOLOGICAL MARKER; ENZALUTAMIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; PROTEIN VARIANT; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ISOPROTEIN; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROTEIN EXPRESSION; RABBIT; RETROSPECTIVE STUDY; VALIDATION STUDY; ANALOGS AND DERIVATIVES; BIOPSY; CELL NUCLEUS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATE; SURVIVAL RATE; TIME FACTOR; TUMOR CELL LINE;

AGED; ANDROSTENES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; CELL LINE, TUMOR; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84964588123     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.03.049     Document Type: Article

References (28)

1. [1] Dehm, S.M., Schmidt, L.J., Heemers, H.V., Vessella, R.L., Tindall, D.J., Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68 (2008), 5469–5477.
2. [2] Nadiminty, N., Tummala, R., Liu, C., et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 12 (2013), 1629–1637.
3. [3] Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
4. [4] Hu, R., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69 (2009), 16–22.
5. [5] Ferraldeschi, R., Welti, J., Luo, J., Attard, G., de Bono, J.S., Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 34 (2015), 1745–1757.
6. [6] Attard, G., Reid, A.H., Yap, T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008), 4563–4571.
7. [7] Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
8. [8] de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
9. [9] Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
10. [10] Hu, R., Lu, C., Mostaghel, E.A., et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72 (2012), 3457–3462.
11. [11] Ware, K.E., Garcia-Blanco, M.A., Armstrong, A.J., Dehm, S.M., Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer 21 (2014), T87–T103.
12. [12] Liu, L.L., Xie, N., Sun, S., Plymate, S., Mostaghel, E., Dong, X., Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33 (2014), 3140–3150.
13. [13] Jenster, G., van der Korput, H.A., van Vroonhoven, C., van der Kwast, T.H., Trapman, J., Brinkmann, A.O., Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5 (1991), 1396–1404.
14. [14] Cao, B., Qi, Y., Zhang, G., et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5 (2014), 1646–1656.
15. [15] Li, Y., Chan, S.C., Brand, L.J., Hwang, T.H., Silverstein, K.A., Dehm, S.M., Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73 (2013), 483–489.
16. [16] Mostaghel, E.A., Marck, B.Y., Plymate, S.R., et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17 (2011), 5913–5925.
17. [17] Watson, P.A., Chen, Y.F., Balbas, M.D., et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107 (2010), 16759–16765.
18. [18] Xu, D., Zhan, Y., Qi, Y., et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res 75 (2015), 3663–3671.
19. [19] Chan, S.C., Selth, L.A., Li, Y., et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res 43 (2015), 5880–5897.
20. [20] Budd, W.T., Seashols-Williams, S.J., Clark, G.C., et al. Dual action of miR-125b as a tumor suppressor and oncomiR-22 promotes prostate cancer tumorigenesis. PLoS One, 10, 2015, e0142373.
21. [21] Liu, G., Sprenger, C., Wu, P.J., et al. MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. Oncotarget 6 (2015), 288–304.
22. [22] Bianchini, D., Omlin, A., Pezaro, C., et al. First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 109 (2013), 2579–2586.
23. [23] Detre, S., Saclani Jotti, G., Dowsett, M., A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48 (1995), 876–878.
24. [24] Ferraldeschi, R., Welti, J., Powers, M.V., et al. Second-generation HSP90 inhibitor Onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. Cancer Res 76 (2016), 2731–2742.
25. [25] Nakazawa, M., Antonarakis, E.S., Luo, J., Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 5 (2014), 265–273.
26. [26] Hornberg, E., Ylitalo, E.B., Crnalic, S., et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One, 6, 2011, e19059.
27. [27] Qu, Y., Dai, B., Ye, D., et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep, 5, 2015, 7654.
28. [28] Efstathiou, E., Titus, M., Wen, S., et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67 (2015), 53–60.